Prevalence and Characteristics of Intimate Partner Violence Against Individuals Seeking Hematological Consultations
- Disease/Condition
- Intimate Partner Violence,Deep Vein Thrombosis (DVT)/Thrombophlebitis,Pulmonary Embolism and Thrombosis
- Study type
- Observational
- Primary sponsor
- Centre Hospitalier Universitaire de Nīmes
- Location
- Nîmes, France
- Phase
- N/A
- Start date
- Jun 01, 2024
- End date
- Jun 01, 2025
- Enrollment
- 3240 participants
Prevalence of patients experiencing Intimate Partner Violence according to consulting department
Intimate violence against individuals, which is particularly marked among women, is one of
 the most widespread human rights violations in the world.
 
 The Women Abuse Screening Tool (WAST) self-questionnaire is a screening tool validated in
 French.
 
 Our preliminary data describing the association between intimate violence against women and
 the first attack of unexplained venous thromboembolic disease, show a significant frequency
 of positive responses to the WAST among women attending a biological hematology consultation
 at the CHU de Nîmes, for reasons of hemostasis disorders (8% out of the first 200 cases).
 
 The study authors wish to establish the prevalence of this situation among patients
 presenting to the CHU de Nîmes for hematological exploration and management. They hypothesize
 that the prevalence of violence against individuals seen in Hematology consultations is
 higher among individuals with hemostasis pathologies (hemorrhagic and thrombotic pathologies)
 than those with cellular pathologies, and higher among women than men.
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT06415968
- Type
- Non-Device Trial
Access comprehensive clinical trial information for NCT06415968 through Pure Global AI's free database. This phase not specified trial is sponsored by Centre Hospitalier Universitaire de Nīmes and is currently Not yet recruiting. The study focuses on Intimate Partner Violence,Deep Vein Thrombosis (DVT)/Thrombophlebitis,Pulmonary Embolism and Thrombosis. Target enrollment is 3240 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.